Cardiff Oncology (CRDF) 10-Q14 Nov 132013 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2013	Nov. 08, 2013
Document and Entity Information	'	'
Entity Registrant Name	'Trovagene, Inc.	'
Entity Central Index Key	'0001213037	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	18,902,991
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$27,799,387	$10,819,781
Accounts receivable	69,566	168,381
Prepaid expenses and other assets	129,393	60,041
Total current assets	27,998,346	11,048,203
Property and equipment, net	740,307	254,742
Other assets	411,912	362,081
Total assets	29,150,565	11,665,026
Current liabilities:	'	'
Accounts payable	158,982	175,679
Accrued expenses	1,054,096	554,691
Current portion of long-term debt	147,618	'
Total current liabilities	1,360,696	730,370
Long-term debt, less current portion	370,431	'
Derivative financial instruments	6,281,284	8,765,628
Total liabilities	8,012,411	9,495,998
Commitments and contingencies (Note 9)	'	'
Stockholders' equity:	'	'
Preferred stock, $0.001 par value, 20,000,000 shares authorized, 60,600 and 95,600 shares outstanding at September 30, 2013 and December 31, 2012, respectively, designated as Series A Convertible Preferred Stock with liquidation preference of $606,000 and $956,000 at September 30, 2013 and December 31, 2012, respectively	60	96
Common stock, $0.0001 par value, 150,000,000 shares authorized,18,891,949 and 15,478,177 issued and outstanding at September 30, 2013 and December 31, 2012, respectively	1,889	1,547
Additional paid-in capital	87,141,485	57,370,017
Deficit accumulated during development stage	-66,005,280	-55,202,632
Total stockholders' equity	21,138,154	2,169,028
Total liabilities and stockholders' equity	$29,150,565	$11,665,026

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Condensed Consolidated Balance Sheets	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares outstanding	60,600	95,600
Series A Convertible Preferred Stock, liquidation preference (in dollars)	$606,000	$956,000
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	18,891,949	15,478,177
Common stock, shares outstanding	18,891,949	15,478,177

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended		170 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Condensed Consolidated Statements of Operations and Comprehensive Loss	'	'	'	'	'
Royalty income	$43,756	$41,500	$211,879	$117,153	$1,137,353
License fees	'	20,000	'	20,000	1,383,175
Milestone fees	'	150,000	'	150,000	150,000
Total revenues	43,756	211,500	211,879	287,153	2,670,528
Costs and expenses:	'	'	'	'	'
Research and development	915,457	511,433	2,661,551	1,326,197	20,111,002
Purchased in process research and development	'	'	'	'	2,666,869
General and administrative	2,205,952	739,042	5,391,932	2,375,666	31,312,048
Total operating expenses	3,121,409	1,250,475	8,053,483	3,701,863	54,089,919
Loss from operations	-3,077,653	-1,038,975	-7,841,604	-3,414,710	-51,419,391
Interest income	44	'	44	'	266,927
Interest expense	-6,263	'	-6,931	'	-1,332,303
Gain on sale of equipment	'	'	'	'	4,000
Amortization of deferred debt costs and original issue discount	'	'	'	'	-2,346,330
Change in fair value of derivative instruments-warrants	-1,317,360	388,750	-2,933,527	-1,824,565	-8,428,326
Gain on extinguishment of debt	'	'	'	'	623,383
Liquidated damages and other forbearance agreement settlement costs	'	'	'	'	-1,758,111
Net loss and comprehensive loss	-4,401,232	-650,225	-10,782,018	-5,239,275	-64,390,151
Preferred stock dividend	-5,360	-9,560	-20,630	-28,680	-366,788
Series A Convertible Preferred stock conversion rate change accreted as a dividend	'	'	'	'	-455,385
Cumulative effect of early adopting ASC Topic 815-40	'	'	'	'	-792,956
Net loss and comprehensive loss available to common stockholders	($4,406,592)	($659,785)	($10,802,648)	($5,267,955)	($66,005,280)
Net loss per common share-basic and diluted (in dollars per share)	($0.25)	($0.05)	($0.66)	($0.42)	'
Weighted average shares outstanding- basic and diluted (in shares)	17,870,703	14,178,733	16,330,313	12,506,789	'

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Stockholders' Equity (Deficiency) (USD $)

Total

Services

Agreement & Plan of Merger with Etherogen, Inc.

Asset Purchase Agreement with MultiGen Diagnostics, Inc.

Founders

Payment of deferred salary to former CEO

Shares issued in connection with Board Compensation

6% convertible debenture

Issuance of shares of common stock in connection with convertible debenture forbearance agreement

Issuance of shares of common stock in payment of convertible debenture interest, in accordance with Forbearance Agreement

Convertible Preferred Stock

Selling agents and finders

Consulting agreements, issuance of common stock or warrants in settlement of consulting services

Settlement of legal fees

Private placement

First tranche of private placement

Second tranche of private placement

Third tranche of a private placement

Private placement

Private placement of common stock October 12, 2007

Private placement of common stock October 16, 2007

Private placement of common stock and warrants to purchase common stock June 12, 2008

Exchange agreement for common stock, warrants to purchase common stock and convertible debenture 2009

Private placement of units

Units issued via registered direct public offering and private placement of units

Preferred Stock

Common Stock

Treasury Shares

Additional Paid-In Capital

Deferred Stock Based Compensation

Deficit Accumulated During Development Stage

Temporary Equity-Unregistered Common Stock

USD ($)

6% convertible debenture

Convertible Preferred Stock

USD ($)

Selling agents and finders

USD ($)

Selling agents and finders

USD ($)

Selling agents and finders

USD ($)

Selling agents and finders

USD ($)

Selling agents and finders

USD ($)

Convertible Preferred Stock

USD ($)

Agreement & Plan of Merger with Etherogen, Inc.

Asset Purchase Agreement with MultiGen Diagnostics, Inc.

Founders

Finder's fees and selling agent fees to shareholder

Payment of deferred salary to former CEO

Shares issued in connection with Board Compensation

Issuance of shares of common stock in connection with convertible debenture forbearance agreement

Conversion of convertible debentures

Issuance of shares of common stock in payment of convertible debenture interest, in accordance with Forbearance Agreement

Consulting agreements, issuance of common stock or warrants in settlement of consulting services

Settlement of legal fees

Private placement

First tranche of private placement

Second tranche of private placement

Third tranche of a private placement

Private placement

Exchange agreement for common stock, warrants to purchase common stock and convertible debenture 2009

Private placement of units

Units issued via registered direct public offering and private placement of units

USD ($)

Services

Agreement & Plan of Merger with Etherogen, Inc.

Asset Purchase Agreement with MultiGen Diagnostics, Inc.

Founders

Finder's fees and selling agent fees to shareholder

Payment of deferred salary to former CEO

Shares issued in connection with Board Compensation

6% convertible debenture

Issuance of shares of common stock in connection with convertible debenture forbearance agreement

Conversion of convertible debentures

Issuance of shares of common stock in payment of convertible debenture interest, in accordance with Forbearance Agreement

Convertible Preferred Stock

Selling agents and finders

Consulting agreements, issuance of common stock or warrants in settlement of consulting services

Settlement of legal fees

Private placement

First tranche of private placement

Second tranche of private placement

Third tranche of a private placement

Private placement

Private placement of common stock October 12, 2007

Private placement of common stock October 16, 2007

Private placement of common stock and warrants to purchase common stock June 12, 2008

Exchange agreement for common stock, warrants to purchase common stock and convertible debenture 2009

Private placement of units

Units issued via registered direct public offering and private placement of units

USD ($)

Private placement

USD ($)

Selling agents and finders

USD ($)

Selling agents and finders

USD ($)

6% convertible debenture

Convertible Preferred Stock

USD ($)

Selling agents and finders

USD ($)

Selling agents and finders

USD ($)

Selling agents and finders

USD ($)

Selling agents and finders

USD ($)

Selling agents and finders

USD ($)

Selling agents and finders

USD ($)

Balance at Aug. 03, 1999

Increase (Decrease) in Stockholders' Equity

Issuance of common stock for cash at $0.0012, $0.003 and other amounts per share

$42,000

$3,700

$38,300

Issuance of common stock for cash at $0.0012, $0.003 and other amounts per share (in shares)

37,000,000

Net loss

-14,760

Balance at Jan. 31, 2000

27,240

3,700

38,300

-14,760

Balance (in shares) at Jan. 31, 2000

37,000,000

Balance at Aug. 03, 1999

Increase (Decrease) in Stockholders' Equity

Common stock issued in lieu of cash for services and other

125,250

Common stock issued in lieu of cash (in shares)

41,750

Warrants reclassified to additional paid in capital

8,735,334

Accretion of preferred stock dividends (restated)

-455,385

Common stock issued in connection with conversion of convertible debentures

1,130,164

Correction of error in derivative liability - fair value of warrants price protected units issued

274,967

Shares issued in connection with purchase agreement

2,771,389

Shares issued in connection with purchase agreement (in shares)

2,043,797

Net loss

-64,390,151

Balance at Sep. 30, 2013

21,138,154

Balance (in shares) at Sep. 30, 2013

60,600

Balance at Jan. 31, 2000

27,240

3,700

38,300

-14,760

Balance (in shares) at Jan. 31, 2000

37,000,000

Increase (Decrease) in Stockholders' Equity

Net loss

-267,599

Balance at Jan. 31, 2001

-240,359

3,700

38,300

-282,359

Balance (in shares) at Jan. 31, 2001

37,000,000

Increase (Decrease) in Stockholders' Equity

Capital contribution of cash

45,188

Net loss

-524,224

Balance at Jan. 31, 2002

-719,395

3,700

83,488

-806,583

Balance (in shares) at Jan. 31, 2002

37,000,000

Increase (Decrease) in Stockholders' Equity

Issuance of common stock for cash at $0.0012, $0.003 and other amounts per share

3,400

126

3,274

Issuance of common stock for cash at $0.0012, $0.003 and other amounts per share (in shares)

1,258,000

Capital contribution of cash

2,500

Net loss

-481,609

Balance at Jan. 31, 2003

-1,195,104

3,826

89,262

-1,288,192

Balance (in shares) at Jan. 31, 2003

38,258,000

Increase (Decrease) in Stockholders' Equity

Net loss

-383,021

Balance at Jan. 31, 2004

-1,578,125

3,826

89,262

-1,671,213

Balance (in shares) at Jan. 31, 2004

38,258,000

Increase (Decrease) in Stockholders' Equity

Issuance of common stock for cash at $0.0012, $0.003 and other amounts per share

2,512,950

2,512,906

Issuance of common stock for cash at $0.0012, $0.003 and other amounts per share (in shares)

440,868

Waiver of founders' deferred compensation

1,655,031

Redemption of shares held by Panetta Partners, Inc.

-500,000

-3,648

-496,352

Redemption of shares held by Panetta Partners, Inc. (in shares)

-36,477,079

Costs associated with recapitalization

-301,499

Share exchange with founders

-38

Share exchange with founders (in shares)

376,334

Issuance of treasury shares

-6

Issuance of treasury shares (in shares)

58,333

Issuance of treasury shares to escrow

-6

Issuance of treasury shares to escrow (in shares)

58,333

-58,333

Issuance of units of common stock and warrants at $6.00, $11.70 and other prices

2,667,900

2,667,877

Issuance of units of common stock and warrants for cash at $6.00, $11.70 and other prices (in shares)

228,026

Issuance of warrants in connection with services

2,630,440

403,038

2,630,440

403,038

Finders and selling agents warrants charged to cost of capital

-403,038

Stock based compensation

1,937,500

-1,937,500

Amortization of deferred stock-based compensation

245,697

Options issued to consultants

1,229,568

Net loss

-5,371,027

Balance at Jan. 31, 2005

3,190,935

289

11,924,689

-1,691,803

-7,042,240

Balance (in shares) at Jan. 31, 2005

2,884,482

Increase (Decrease) in Stockholders' Equity

Issuance of common stock for cash at $0.0012, $0.003 and other amounts per share (in shares)

17,094

252,564

Private placement of preferred stock and warrants for cash at $10.00 per share (restated) (in shares)

277,100

Common stock issued in lieu of cash for services and other

16,500

Common stock issued in lieu of cash (in shares)

833

4,077

Private placement of preferred stock and warrants for cash at $10.00 per share (restated)

2,771,000

277

2,770,723

Issuance of units of common stock and warrants at $6.00, $11.70 and other prices

200,000

2,954,999

199,998

2,954,974

Issuance of warrants in connection with services

167,397

222,188

167,397

222,188

Finders and selling agents warrants charged to cost of capital

-167,397

-222,188

-167,397

-222,188

Derivative liability-warrants at issuance

-567,085

Stock based compensation

2,928,298

Amortization of deferred stock-based compensation

645,832

Accretion of preferred stock dividends (restated)

792,956

-792,956

Return of treasury shares from escrow

-6

Return of treasury shares from escrow (in shares)

-58,333

58,333

Retirement of treasury shares

-6

Retirement of treasury shares (in shares)

-58,333

Payment of finder fees, selling agent fees and expenses in cash

-277,102

-179,600

-298,000

-277,102

-179,600

-298,000

Preferred stock dividend

-60,741

Net loss

-7,844,326

Balance at Jan. 31, 2006

3,480,710

277

310

20,266,357

-1,045,971

-15,740,263

Balance (in shares) at Jan. 31, 2006

277,100

3,100,717

Increase (Decrease) in Stockholders' Equity

Issuance of common stock for cash at $0.0012, $0.003 and other amounts per share (in shares)

125,787

166,667

Common stock issued in lieu of cash for services and other

9,566

Common stock issued in lieu of cash (in shares)

1,449

Issuance of common stock and warrant as finder's fees (in shares)

27,425

Issuance of units of common stock and warrants at $6.00, $11.70 and other prices

943,401

943,388

1,000,000

Issuance of warrants in connection with services

101,131

55,568

101,131

55,568

Finders and selling agents warrants charged to cost of capital

-55,568

Issuance of 27,425 units to finder

167,856

Stock based compensation

1,572,545

Conversion of preferred stock and issuance of common stock

160

Conversion of preferred stock and issuance of common stock (in shares)

-174,000

Conversion of preferred stock and issuance of common stock

-174

Number of shares issued upon conversion of preferred stock into common stock

137,739

Implementation of ASC 718

-1,045,971

1,045,971

Value attributed to warrants issued with 6% convertible debentures

1,991,822

Payment of finder fees, selling agent fees and expenses in cash

-118,341

-80,000

Preferred stock dividend

-59,164

Reclassification of derivative financial instruments to stockholders' equity upon adoption of ASC 815-40

111,700

567,085

-455,385

Derivative liability-fair value of warrants and price protected units issued

-15,000

Donated services

62,500

Net loss

-7,134,067

Balance at Jan. 31, 2007

905,000

Balance at Jan. 31, 2007

1,129,659

103

337

24,518,098

-23,388,879

Balance (in shares) at Jan. 31, 2007

166,667

Balance (in shares) at Jan. 31, 2007

103,100

3,365,692

Increase (Decrease) in Stockholders' Equity

Issuance of common stock for cash at $0.0012, $0.003 and other amounts per share

850,000

849,972

Issuance of common stock for cash at $0.0012, $0.003 and other amounts per share (in shares)

283,333

Issuance of warrants in connection with services

45,403

Finders and selling agents warrants charged to cost of capital

-45,403

Derivative liability-warrants at issuance

-45,371

Stock based compensation

914,847

Conversion of preferred stock and issuance of common stock

Conversion of preferred stock and issuance of common stock (in shares)

-7,500

Conversion of preferred stock and issuance of common stock

-7

Number of shares issued upon conversion of preferred stock into common stock

7,813

Payment of finder fees, selling agent fees and expenses in cash

-51,733

Preferred stock dividend

-35,054

Donated services

275,000

Net loss

-4,683,141

Balance at Dec. 31, 2007

-1,645,793

366

26,460,819

-28,107,074

Balance (in shares) at Dec. 31, 2007

95,600

3,656,838

Balance at Dec. 31, 2007

905,000

Balance (in shares) at Dec. 31, 2007

166,667

Increase (Decrease) in Stockholders' Equity

Issuance of common stock for cash at $0.0012, $0.003 and other amounts per share

1,145,000

1,144,967

Issuance of common stock for cash at $0.0012, $0.003 and other amounts per share (in shares)

330,682

Derivative liability-warrants at issuance

-201,122

Stock based compensation

543,697

Common stock issued in connection with conversion of convertible debentures

93,641

93,638

Conversion of debenture to common stock (in shares)

31,214

Payment of finder fees, selling agent fees and expenses in cash

-74,500

Preferred stock dividend

-38,240

Reclassification of common stock initially recorded as temporary equity

905,000

904,983

-905,000

Reclassification of common stock initially recorded as temporary equity (in shares)

166,667

-166,667

Donated services

390,750

Net loss

-5,166,240

Balance at Dec. 31, 2008

-4,047,807

419

29,263,232

-33,311,554

Balance (in shares) at Dec. 31, 2008

95,600

4,185,401

Increase (Decrease) in Stockholders' Equity

Issuance of common stock for cash at $0.0012, $0.003 and other amounts per share

1,465,000

1,464,951

Issuance of common stock for cash at $0.0012, $0.003 and other amounts per share (in shares)

488,333

Common stock issued in lieu of cash for services and other

1,739,959

112,291

1,739,868

112,285

Common stock issued in lieu of cash (in shares)

906,245

60,147

159,630

68,897

Issuance of units of common stock and warrants at $6.00, $11.70 and other prices

478,890

306,737

478,874

306,730

Stock based compensation

177,836

Preferred stock dividend

-38,240

Derivative liability-fair value of warrants and price protected units issued

-1,497,568

Net loss

-2,483,807

Balance at Dec. 31, 2009

-3,786,709

588

32,046,208

-35,833,601

Balance (in shares) at Dec. 31, 2009

95,600

5,868,653

Increase (Decrease) in Stockholders' Equity

Common stock issued in lieu of cash for services and other

115,971

100,000

-8

115,962

99,997

Common stock issued in lieu of cash (in shares)

79,333

12,745

85,619

70,833

29,240

Issuance of units of common stock and warrants at $6.00, $11.70 and other prices

28,346

212,500

1,734,700

28,345

212,493

1,734,642

Issuance of units of common stock and warrants for cash at $6.00, $11.70 and other prices (in shares)

578,233

Stock based compensation

325,930

Preferred stock dividend

-38,240

Derivative liability-fair value of warrants and price protected units issued

-1,010,114

Shares issued in connection with purchase agreement

2,771,389

204

2,771,185

Shares issued in connection with purchase agreement (in shares)

2,043,797

Net loss

-5,449,138

Balance at Dec. 31, 2010

-4,995,365

878

36,324,640

-41,320,979

Balance (in shares) at Dec. 31, 2010

95,600

8,768,453

Increase (Decrease) in Stockholders' Equity

Common stock issued in lieu of cash for services and other

125,250

85,275

175,000

-9

125,246

85,269

174,994

Common stock issued in lieu of cash (in shares)

90,258

41,750

64,214

58,333

Issuance of units of common stock and warrants at $6.00, $11.70 and other prices

2,573,500

2,573,415

Issuance of units of common stock and warrants for cash at $6.00, $11.70 and other prices (in shares)

857,833

Stock based compensation

250,978

Common stock issued in connection with conversion of convertible debentures

1,130,164

1,130,079

Conversion of debenture to common stock (in shares)

856,185

Preferred stock dividend

-38,240

Derivative liability-fair value of warrants and price protected units issued

-1,298,618

Net loss

-2,239,212

Balance at Dec. 31, 2011

-4,231,268

1,073

39,365,994

-43,598,431

Balance (in shares) at Dec. 31, 2011

95,600

10,737,026

Increase (Decrease) in Stockholders' Equity

Common stock issued in lieu of cash for services and other

22,381

22,380

Common stock issued in lieu of cash (in shares)

9,916

Issuance of common stock and warrant as finder's fees (in shares)

214,100

Issuance of units of common stock and warrants at $6.00, $11.70 and other prices

16,900,000

438

-21

16,899,562

Issuance of units of common stock and warrants for cash at $6.00, $11.70 and other prices (in shares)

4,383,333

Issuance of warrants in connection with services

142,508

Warrants reclassified to additional paid in capital

3,317,463

Stock based compensation

532,140

Issuance of common stock upon exercise of stock options

600

Issuance of common stock upon exercise of stock options (in shares)

200

Issuance of common stock upon net exercise of warrant

-1

Issuance of common stock upon net exercise of warrant (in shares)

8,602

Payment of finder fees, selling agent fees and expenses in cash

-1,576,452

Preferred stock dividend

-38,240

Correction of error in derivative liability - fair value of warrants price protected units issued

274,967

Derivative liability-fair value of warrants and price protected units issued

-1,796,610

Shares issued in connection with purchase agreement

187,500

187,487

Shares issued in connection with purchase agreement (in shares)

125,000

Net loss

-11,565,961

Balance at Dec. 31, 2012

2,169,028

1,547

57,370,017

-55,202,632

Balance (in shares) at Dec. 31, 2012

95,600

15,478,177

Increase (Decrease) in Stockholders' Equity

Sale of common stock, net of expenses

18,897,388

263

18,897,125

Sale of common stock, net of expenses (in shares)

2,631,332

Issuance of warrants in connection with services

198,791

Warrants reclassified to additional paid in capital

5,417,871

Stock based compensation

1,657,893

Issuance of common stock upon exercise of stock options

-2

Issuance of common stock upon exercise of stock options (in shares)

41,667

22,955

Issuance of common stock upon net exercise of warrant

-1

Issuance of common stock upon net exercise of warrant (in shares)

7,284

Issuance of common stock upon exercise of warrant

3,599,831

3,599,759

Issuance of common stock upon exercise of warrant (in shares)

715,743

Conversion of preferred stock and issuance of common stock

Conversion of preferred stock and issuance of common stock (in shares)

-35,000

Conversion of preferred stock and issuance of common stock

-36

Number of shares issued upon conversion of preferred stock into common stock

36,458

Preferred stock dividend

-20,630

Net loss

-10,782,018

Balance at Sep. 30, 2013

$21,138,154

$60

$1,889

$87,141,485

($66,005,280)

Balance (in shares) at Sep. 30, 2013

60,600

18,891,949

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Stockholders' Equity (Deficiency) (Parenthetical) (USD $)	12 Months Ended				6 Months Ended	12 Months Ended
	Jan. 31, 2007	Jan. 31, 2006	Jan. 31, 2005	Jan. 31, 2003	Jan. 31, 2000	Jan. 31, 2006	Jan. 31, 2006
					Founders	Series A Convertible Preferred Stock	Third and final tranche of a private placement of units of common stock and warrants to purchase common stock 2005
						Warrants	Selling agents and finders
						Selling agents and finders
Issuance of common stock for cash (in dollars per share)	'	'	'	$0.00	$0.00	'	'
Issuance of common stock and warrants for cash (in dollars per share)	$6	'	$11.70	'	'	'	'
Issuance of warrants to selling agents (in shares)	15,779	'	20,610	'	'	17,572	20,205
Issuance of preferred stock and warrants for cash (in dollars per share)	'	$10	'	'	'	'	'
Interest rate, convertible debenture (as a percent)	6.00%	'	'	'	'	'	'

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended		170 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2013
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	MultiGen Diagnostics, Inc.
Operating activities	'	'	'	'
Net loss	($10,782,018)	($5,239,275)	($64,390,151)	'
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'	'
Non-cash interest expense	2,085	'	2,085	'
Depreciation and amortization	85,532	26,331	345,173	'
Stock based compensation expense	1,856,684	349,010	13,869,149	'
Founders', compensation contributed to equity	'	'	1,655,031	'
Donated services contributed to equity	'	'	829,381	'
Settlement of consulting services in stock	'	'	478,890	'
Amortization of deferred debt costs and original issue discount	'	'	2,346,330	'
Liquidated damages and other forbearance agreement settlement costs paid in stock	'	'	1,758,111	'
Interest expense on convertible debentures paid in stock	'	'	757,198	'
Change in fair value of financial instruments	2,933,527	1,824,565	8,428,326	'
Gain on extinguishment of debt	'	'	-623,383	'
Purchased in process research and development expense-related party	'	'	2,666,869	'
Stock issued in connection with payment of deferred salary	'	'	28,346	'
Stock issued in connection with settlement of legal fees	'	'	100,000	'
Stock and warrant issued in connection with consulting services	'	164,889	452,389	'
Changes in operating assets and liabilities:	'	'	'	'
Increase in other assets	-49,831	'	-119,712	'
Decrease (increase) in accounts receivable	98,815	-29,048	-69,567	'
Increase in prepaid expenses	-69,352	-14,594	-129,393	'
Increase (decrease) in accounts payable, accrued expenses and other	462,078	-701,019	1,140,697	'
Net cash used in operating activities	-5,462,480	-3,619,141	-30,474,231	'
Investing activities:	'	'	'	'
Assets acquired in Etherogen, Inc. merger	'	'	-104,700	'
Capital expenditures	-571,097	-212,220	-1,085,480	'
Net cash used in investing activities	-571,097	-212,220	-1,190,180	'
Financing activities	'	'	'	'
Proceeds from sale of 6% convertible debenture	'	'	2,335,050	'
Debt issuance costs	'	'	-297,104	'
Proceeds from sale of common stock, net of expenses	18,897,388	10,946,115	51,652,940	'
Proceeds from exercise of warrants	3,599,831	'	3,599,830	'
Proceeds from exercise of options	'	'	600	'
Proceeds from a non-exclusive selling agent's agreement	'	'	142,187	'
Borrowings under capital lease line	515,964	'	515,964	'
Costs associated with recapitalization	'	'	-362,849	'
Proceeds from sale of preferred stock	'	'	2,771,000	'
Payment of finders' fee on preferred stock	'	'	-277,102	'
Redemption of common stock	'	'	-500,000	'
Payment of preferred stock dividends	'	'	-116,718	'
Net cash provided by financing activities	23,013,183	10,946,115	59,463,798	'
Net change in cash and equivalent	16,979,606	7,114,754	27,799,387	'
Cash and cash equivalents-Beginning of period	10,819,781	700,374	'	'
Cash and cash equivalents-End of period	27,799,387	7,815,128	27,799,387	'
Supplementary disclosure of cash flow activity:	'	'	'	'
Cash paid for taxes	7,650	'	7,650	'
Cash paid for interest	3,339	'	3,339	'
Supplemental disclosure of non-cash investing and financing activities:	'	'	'	'
Issuance of common stock pursuant to acquisitions	'	'	'	187,500
Reclassification of derivative financial instruments to additional paid in capital	-5,417,871	-3,317,463	-8,735,334	'
Correction of error in derivative financial instruments	'	-274,967	-274,967	'
Issuance of 41,750 shares of common stock for Board of Directors' fees in lieu of cash payment	'	'	125,250	'
Conversion of $2,335,050 of 6% debentures	'	'	1,130,164	'
Series A Preferred beneficial conversion feature accreted as a dividend	'	'	455,385	'
Preferred stock dividends accrued	20,630	28,680	217,715	'
Interest paid on common stock	'	'	$1,325,372	'

Condensed_Consolidated_Stateme4

Condensed Consolidated Statements of Cash Flows (Parenthetical) (USD $)	170 Months Ended	9 Months Ended		170 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
	Sep. 30, 2013	MultiGen Diagnostics, Inc.	MultiGen Diagnostics, Inc.	MultiGen Diagnostics, Inc.
Condensed Consolidated Statements of Cash Flows	'	'	'	'
Interest rate, convertible debenture (as a percent)	6.00%	'	'	'
Issuance of common stock for Board of Directors' fees in lieu of cash payment, shares	41,750	'	'	'
Conversion of debentures (in dollars)	$2,335,050	'	'	'
Statement	'	'	'	'
Common stock issued in connection with an asset purchase agreement (in shares)	'	125,000	125,000	125,000

Business_Overview_and_Basis_of

Business Overview and Basis of Presentation	9 Months Ended
Business Overview and Basis of Presentation	Sep. 30, 2013
Business Overview and Basis of Presentation	'
Business Overview and Basis of Presentation	'
	1. Business Overview and Basis of Presentation

	Business Overview

	Trovagene, Inc (“Trovagene” or the “Company”) is a developer of cell-free molecular diagnostics that is leveraging its innovative, non-invasive cancer monitoring technology to detect and quantify oncogene mutations and genetic variations in cancer patients. Trovagene’s technology applies ultra-sensitive droplet digital PCR and high-throughput next generation sequencing techniques to analyze cell-free nucleic acid specimens obtained from urine samples.

	When medical professionals utilize targeted cancer therapies, it is crucial that they monitor patients for the presence or emergence of oncogene mutations that are indicative of either responsiveness or resistance to the respective treatment. Changes in oncogene mutation frequency can provide clinically actionable information about treatment response, disease progression, or disease recurrence. Monitoring patients throughout the course of their cancer may also reveal mutational changes that occur under the pressure of treatment, or if the tumor metastasizes.

	For most patients, the presence or absence of clinically relevant mutations is determined at diagnosis through a tissue biopsy. However, a growing body of evidence suggests that, due to the heterogeneity of tumor tissue, a given biopsy sample is not necessarily representative of a patient’s oncogene mutation status. Cell-free nucleic acids overcome this limitation. While cell-free nucleic acids can be obtained from blood samples, oncogene mutations are often rare events and the volume and sampling frequency restrictions associated with blood samples represent practical limitations. In contrast, urine sampling does not require the assistance of a healthcare professional, and samples can be obtained frequently and in large volumes, overcoming the restrictions associated with blood and enabling better detection. Trovagene has pioneered the discovery of cell-free nucleic acids in urine and developed proprietary technologies to extract, purify, detect, and quantify such cell-free nucleic acids from urine samples. The Company operates a CLIA-certified (under the regulations of the State of California and accredited by the College of American Pathologists (CAP) high complexity molecular diagnostic laboratory in San Diego, CA.

	Clinical studies are underway to establish the clinical utility of the Company’s platform for monitoring tumor dynamics as well as individual responses to both targeted and non-targeted treatments. Further expansion of our monitoring capabilities will include additional mutational markers with known clinical utility, as well as known genomic alternations that indicate resistance to therapy.

	Basis of Presentation

	The accompanying unaudited condensed consolidated financial statements of Trovagene, which include its wholly owned subsidiary Xenomics, Inc., a California corporation (“Xenomics Sub”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). All intercompany balances and transactions have been eliminated. Certain items in the comparable prior period’s financial statements have been reclassified to conform to the current period’s presentation. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements as of December 31, 2012 and December 31, 2011 and for each of the two years ended December 31, 2012 and from inception (August 4, 1999) to December 31, 2012 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 1, 2013. The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at September 30, 2013, and for all periods presented herein, have been made. The results of operations for the periods ended September 30, 2013 and 2012 are not necessarily indicative of the operating results for the full year.

	On May 24, 2012, the Board of Directors approved a 1-for-6 reverse stock split of the Company’s issued and outstanding common stock effective on May 29, 2012. All the relevant information relating to number of shares and per share information contained in these consolidated financial statements has been retrospectively adjusted to reflect the reverse stock split for all periods presented.

Net_Loss_Per_Share

Net Loss Per Share	9 Months Ended
Net Loss Per Share	Sep. 30, 2013
Net Loss Per Share	'
Net Loss Per Share	'
	2. Net Loss Per Share

	Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, for all periods presented. In accordance with this guidance, basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. In a period where there is a net loss position, diluted weighted-average shares are the same as basic weighted-average shares. Shares used in calculating basic and diluted net loss per common share for the three and nine months ended September 30 exclude as antidilutive the following share equivalents:

		September 30,
		2013	2012
	Options to purchase Common Stock	3,894,044	3,295,066
	Warrants to purchase Common Stock	6,306,582	5,729,754
	Series A Convertible Preferred Stock	63,125	99,583
		10,263,751	9,124,403

Accounting_for_ShareBased_Paym

Accounting for Share-Based Payments	9 Months Ended
Accounting for Share-Based Payments	Sep. 30, 2013
Accounting for Share-Based Payments	'
Accounting for Share-Based Payments	'
	3. Accounting for Share-Based Payments

	Stock Options

	ASC Topic 718 “Compensation—Stock Compensation” requires companies to measure the cost of employee services received in exchange for the award of equity instruments based on the estimated fair value of the award at the date of grant. The expense is to be recognized over the period during which an employee is required to provide services in exchange for the award. ASC Topic 718 did not change the way Trovagene accounts for non-employee stock-based compensation. Trovagene accounts for shares of common stock, stock options and warrants issued to non-employees based on the fair value of the stock, stock option or warrant, if that value is more reliably measurable than the fair value of the consideration or services received. The Company accounts for stock options issued and vesting to non-employees in accordance with ASC Topic 505-50 “Equity-Based Payment to Non-Employees” whereas the value of the stock compensation is based upon the measurement date as determined at either: a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Accordingly the fair value of these options is being “marked to market” quarterly until the measurement date is determined.

	Stock-based compensation expense related to Trovagene options have been recognized in operating results as follow:

		Three Months						Nine Months
		Ended September 30,						Ended September 30,
		2013			2012			2013		2012
	Included in research and development expense	$	124,447		$	37,399		$	426,656	$	68,879
	Included in general and administrative expense	844,629			92,960			1,231,237		280,131
	Total stock-based compensation expense	$	969,076		$	130,359		$	1,657,893	$	349,010

	During the quarter ended September 30, 2013, an option to purchase 90,000 shares of common stock was granted to a Board Director for services provided outside of routine Board of Directors’ services. The fair value of this option was approximately $500,000 and is included in general and administrative expenses.

	The unrecognized compensation cost related to non-vested stock options outstanding at September 30, 2013 and 2012, net of expected forfeitures, was $3,170,227 and $1,457,061, respectively, to be recognized over a weighted-average remaining vesting period of approximately three and four years, respectively.

	The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following assumptions during the following periods indicated.

		Nine Months		Nine Months
		Ended		Ended
		September		September
		30, 2013		30, 2012
	Risk-free interest rate	0.74-1.48	%	0.62-1.04	%
	Dividend yield	0	%	0	%
	Expected volatility	95-100	%	90	%
	Expected term (in years)	5 yrs		5 yrs

	A summary of stock option activity and of changes in stock options outstanding under the Plan is presented below:

		Number of		Weighted Average			Intrinsic
		Options		Exercise Price			Value
				Per Share
	Balance outstanding, December 31, 2012	3,711,303		$	4.69
	Granted	710,427		$	6.69
	Exercised	(41,667	)	$	4.5
	Forfeited	(486,019	)	$	4.32
	Balance outstanding, September 30, 2013	3,894,044		$	5.11		$	9,645,929
	Exercisable at September 30, 2013	2,084,383		$	5.6		$	4,770,228

	During the quarter ended June 30, 2013, the Company had issued 260,000 options over the authorized number of options in the Plan. As per ASC Topic 815-40, the options were accounted for as liabilities and recorded at fair value with the changes in fair value being recorded in the Company’s statement of operations. Stockholder approval was obtained on July 18, 2013 to increase the number of authorized shares in the Plan from 3,666,667 to 6,000,000. Accordingly, the options were remeasured as of the date of stockholder approval with the change recorded in stock based compensation expense and the $23,024 liability was reclassified to additional paid in capital.

	Warrants

	A summary of warrant activity is presented below:

		Number		Weighted			Remaining
		of		Average			Contractual Term
		Warrants		Exercise			Years
				Price
	Balance outstanding, December 31, 2012	6,985,070		$	3.96		5.41
	Granted	50,000		$	8		2.38
	Exercised	(728,488	)	$	4.99		4.34
	Balance outstanding, September 30, 2013	6,306,582		$	3.88		4.68

	The Company issued a warrant to purchase 50,000 shares of common stock at an exercise price of $8.00 per share, during the nine months ended September 30, 2013. The warrants were issued in connection with an agreement to provide services related to investor and public relations materials and expire three years from date of grant. The estimated fair value of the warrant was determined on the date of grant using the Black-Scholes option valuation model using the following assumptions: a risk-free interest rate of 0.42%, dividend yield of 0%, expected volatility of 97% and expected term of three years. The resulting fair value of $198,791 was recorded as stock based compensation expense.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
Stockholders' Equity	Sep. 30, 2013
Stockholders' Equity	'
Stockholders' Equity	'
	4. Stockholders’ Equity

	Common Stock

	During the nine month period ended September 30, 2013, the Company issued a total of 3,413,772 shares of Common Stock. The Company sold 2,631,332 shares of Common Stock for net proceeds of $18,897,388. See Note 9 - Public Offering and Controlled Equity Offering. In addition, 36,458 shares were issued upon conversion of Series A Preferred Stock, 715,743 shares were issued upon exercise of warrants for a weighted average price of $5.02 and 7,284 shares were issued upon net exercise of 12,745 warrants at an exercise price of $3.00. The remaining 22,955 shares were issued upon net exercise of an option for 41,667 shares at an exercise price of $4.50.

	Series A Convertible Preferred Stock

	During the nine month period ended September 30, 2013, 35,000 shares of Series A Convertible Preferred Stock were converted into 36,458 shares of common stock, on a net converted basis. As of September 30, 2013, 60,600 shares of Series A Convertible Preferred were outstanding.

Asset_Purchase_Agreement

Asset Purchase Agreement	9 Months Ended
Asset Purchase Agreement	Sep. 30, 2013
Asset Purchase Agreement	'
Asset Purchase Agreement	'
	5. Asset Purchase Agreement

	On February 1, 2012 the Company entered into an asset purchase agreement with MultiGen Diagnostics, Inc. The Company determined that the acquired asset does not meet the definition of a business, as defined in ASC 805, Business Combinations and will be accounted for under ASC 350, Intangibles- Goodwill and Other. In connection with the acquisition, the Company issued 125,000 shares of restricted common stock to MultiGen. In addition, up to an additional $3.7 million may be paid in a combination of common stock and cash to MultiGen upon the achievement of specific sales and earnings targets. In addition, in connection with the acquisition, the Company entered into a Reagent Supply Agreement dated as of February 1, 2012 pursuant to which MultiGen will supply and deliver reagents to be used in connection with a Clinical Laboratory Improvement Amendment (CLIA) laboratory. The total purchase consideration was determined to be $187,500 which was paid in the Company’s common stock.

	Under ASC Topic 805, Business Combinations, the Company was required to assess the fair value of the assets acquired and the contingent consideration at the date of acquisition. Therefore, the Company assessed the fair value of the assets purchased and concluded that the purchase price would be allocated entirely to one intangible asset, a CLIA license. The contingent consideration of the $3.7 million milestone was determined to have no fair value by applying a weighted average probability on the achievement of the milestones developed during the valuation process. The Company will assess the fair value of the contingent consideration at each quarter and make adjustments as necessary until the milestone dates have expired. As of September 30, 2013, no adjustments to the fair value of the contingent consideration have been necessary, and therefore the fair value of the contingent consideration remains unchanged.

Derivative_Financial_Instrumen

Derivative Financial Instruments - Warrants	9 Months Ended
	Sep. 30, 2013
Derivative Financial Instruments - Warrants	'
Derivative Financial Instruments - Warrants	'
	6. Derivative Financial Instruments - Warrants

	Effective January 1, 2009, the Company adopted provisions of ASC Topic 815-40, “Derivatives and Hedging: Contracts in Entity’s Own Equity” (“ASC Topic 815-40”). ASC Topic 815-40 clarifies the determination of whether an instrument issued by an entity (or an embedded feature in the instrument) is indexed to an entity’s own stock, which would qualify as a scope exception under ASC Topic 815-10.

	Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, Trovagene has determined that the warrants issued in connection with certain of its private placements and with its debentures must be recorded as derivative liabilities. Accordingly the warrants are also being re-measured at each balance sheet date based on estimated fair value, and any resultant changes in fair value is being recorded in the Company’s statement of operations.

	The Company estimates the fair value of the warrants issued in connection with certain of its private placements and with its debentures using the Black-Scholes model in order to determine the associated derivative instrument liability and change in fair value described above. The range of assumptions used to determine the fair value of the warrants during each nine month period, September 30, 2013 and 2012 were as follows:

		Nine Months Ended			Nine Months Ended
		September 30, 2013			September 30, 2012
	Estimated fair value of Trovagene common stock	$	6.26-7.18		$	1.20-3.07
	Expected warrant term	1 months — 5.8 years			1 month - 6 years
	Risk-free interest rate	0.03-1.41%			0.09-0.92%
	Expected volatility	95 -100%			90%
	Dividend yield	0%			0%


	The following table sets forth the components of changes in the Company’s derivative financial instruments liability balance, valued using the Black-Scholes option pricing method, for the periods indicated:

	Date	Description		Warrants		Derivative
						Instrument
						Liability

	December 31, 2012	Balance of derivative financial instruments liability		1,087,060		$	6,252,760

		Change in fair value of warrants during the nine months ended September 30, 2013 recognized as a loss in the statement of operations		—		28,524

	September 30, 2013	Balance of derivative financial instruments liability		1,087,060		$	6,281,284

	The Company has issued units that were price protected. Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, Trovagene has determined that these price protected units issued in connection with the private placements must be recorded as derivative liabilities. Accordingly the warrants are also being re-measured at each balance sheet date based on estimated fair value, and any resultant changes in fair value is being recorded in the Company’s statement of operations. The fair value of these price protected units was estimated using the binomial option pricing model. The binomial model requires the input of variable inputs over time, including the expected stock price volatility, the expected price multiple at which unit holders are likely to exercise their warrants and the expected forfeiture rate. The Company uses historical data to estimate forfeiture rate and expected stock price volatility within the binomial model. The risk-free rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve in effect at the date of grant for the expected term of the warrant. However, the completion of the public offering in July 2013 removed the condition which required these warrants to be treated as derivative liabilities. Accordingly, the fair value of these warrants were marked to market through July 18, 2013 and then reclassified from a liability to additional paid in capital.

	The following table sets forth the components of changes in the Company’s derivative financial instruments liability balance, valued using the Binomial option pricing method, for the periods indicated:

	Date	Number of		Derivative			Change In			Ending
		Price Protected		Liability For			Fair			Balance
		Units		Issued Units			value of			Derivative
							Derivative			Liability
							Liability For
							Previously
							Outstanding
							Price
							Protected
							Units
	December 31, 2012	1,288,650		$	1,171,463		$	1,341,405		$	2,512,868
	Reclassification of derivative liability to equity	(1,288,650	)				(5,417,871		)	(5,417,871		)
	Change in fair value of warrants during the nine months ended September 30, 2013 recognized as a loss in the statement of operations	—		—			2,905,003			2,905,003
	September 30, 2013	—		$	1,171,463		$	(1,171,463	)	$	—

	At September 30, 2013 and December 31, 2012, the total fair value of the above warrants accounted for as derivative financial instruments, valued using the Black-Scholes option pricing model and the Binomial option pricing model was $6,281,284 and $8,765,628, respectively, and is classified as derivative financial instruments liability on the balance sheet.

Fair_Value_Measurements

Fair Value Measurements

9 Months Ended

Sep. 30, 2013

Fair Value Measurements

7. Fair Value Measurements

Fair value of financial instruments

The Company has adopted ASC 820 Fair Value Measurements and Disclosures (“ASC 820”) for financial assets and liabilities that are required to be measured at fair value, and non-financial assets and liabilities that are not required to be measured at fair value on a recurring basis. Financial instruments consist of cash and cash equivalents, accounts receivable and accounts payable. These financial instruments are stated at their respective historical carrying amounts which approximate fair value due to their short term nature.

The following tables present the Company’s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December 31, 2012 and September 30, 2013:

Liabilities:

Quoted Prices

Significant

Balance as of

Other

Unobservable

December 31, 2012

Active

Observable

Inputs

Markets

Inputs

(Level 3)

for Identical

(Level 2)

Assets and

Liabilities

(Level 1)

Derivative liabilities related to warrants

—

8,765,628

Quoted Prices

Significant

Balance as of

Other

Unobservable

September 30,

Active

Observable

Inputs

2013

Markets

Inputs

(Level 3)

for Identical

(Level 2)

Assets and

Liabilities

(Level 1)

Assets:

Money market fund (1)

27,000,044

—

27,000,044

Liabilities:

Derivative liabilities related to warrants

—

6,281,284

(1)Included as a component of cash and cash equivalents on the accompanying consolidated condensed balance sheet.

The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the nine months ended September 30, 2013:

Description

Balance at

Fair Value of

Fair value of

Unrealized

Balance as of

December 31,

Warrants

New Warrants

(gains) or

September 30,

2012

Reclassified to

Issued During

losses

2013

Additional Paid in

the Period

Capital

Derivative liabilities related to Warrants

8,765,628

(5,417,871

)

—

2,933,527

6,281,284

The unrealized gains or losses on the derivative liabilities are recorded as a change in fair value of derivative liabilities in the Company’s statement of operations. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, the Company reviews the assets and liabilities that are subject to ASC Topic 815-40. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.

Debt

Debt	9 Months Ended
Debt	Sep. 30, 2013
Debt	'
Debt	'
	8. Debt

	Equipment Line of Credit

	In June 2013, the Company entered into a Loan and Security Agreement with Silicon Valley Bank that provides for cash borrowings for equipment of up to $1.0 million, secured by the equipment financed. As of September 30, 2013, $515,964 has been borrowed under the agreement. As of September 30, 2013, amounts due under the agreement include $147,618 in current liabilities and $370,431 in long-term liabilities, which includes $2,085 of accrued interest.

	Under the terms of the agreement, interest is the greater of 5% or 4.6% above the U.S. Treasury Note as of the date of each borrowing. Interest only payments are due on borrowings through December 31, 2013, with both interest and principal payments commencing in January 2014. Any equipment advances after December 31, 2013 are subject to principal and interest payments immediately over a 30 month period following the advance. The Company has an obligation to make a final payment equal to 7% of total amounts borrowed at the loan maturity date and the final payment is being accrued over the term of the loans using the effective-interest method.

	At September 30, 2013, Trovagene was in compliance with all covenants under the Loan Agreement. The Company is subject to certain nonfinancial covenants and a material adverse change clause.

	The Company recorded $6,931 in interest expense related to the Loan and Security Agreement during the nine months ended September 30, 2013. Closing costs were not material and were expensed to general and administrative expenses in June 2013.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2013
Commitments and Contingencies	'
Commitments and Contingencies	'
	9. Commitments and Contingencies

	Research and Development Agreements

	During 2012, the Company entered into research agreements with University of Texas MD Anderson Cancer Center (“MDACC”) to provide samples and evaluate methods used by the Company in identification of pancreatic cancer mutations, as well as to measure the degree of concordance between results of transrenal DNA mutations analysis from urine samples and tumor tissue. Under these agreements, the Company has committed to pay $152,900 for the services performed by the University. As of September 30, 2013, the Company has incurred and recorded $107,740 of research and development expenses related to these agreements.

	On April 25, 2013 the Company entered into a Research and Development Agreement with PerkinElmer Health Sciences, Inc. (“PerkinElmer”) pursuant to which the Company will design an assay, based on the Company’s TrNA technology, to determine the risk for developing hepatocellular carcinoma. The Company and PerkinElmer will jointly validate the assay and evaluate the potential of combining the Company’s TrNA technology with PerkinElmer’s technology for automation of nucleic acid isolation. PerkinElmer will pay the Company certain milestone payments. In addition, the Company has granted PerkinElmer an exclusive option (the “HCC Option”) to obtain an exclusive royalty-bearing license to use the Company’s technology within the hepatocellular carcinoma field (the “HCC Field”). Such option is exercisable within 15 days of the end of proof of principle work on the hepatocellular carcinoma assay. In the event PerkinElmer exercises such option, the Company and PerkinElmer shall have a 60 day period to negotiate a license agreement. If both parties cannot agree on the terms of a license agreement during such period, for a period of one year, and if the Company wishes to enter into a license agreement with a third party pursuant to which the Company shall grant to such third party a license on terms that are in the aggregate more favorable to the Company than the terms last offered by the Company to PerkinElmer, then the Company shall, prior to entering into such license agreement, first offer to enter into such license agreement with PerkinElmer instead of such third party.

	The Company has also granted PerkinElmer an exclusive option to obtain an exclusive royalty-bearing license to use the Company’s technology in other fields. Such option is exercisable within 15 days of the completion of the proof of principle work for the HCC assay development. In the event PerkinElmer exercises such option, the Company and PerkinElmer shall have a 60 day period to negotiate a license agreement. If both parties cannot agree on the terms of a license agreement during such period or the option is not exercised by PerkinElmer, the Company shall be free to license such technology to any party.

	The Company recognizes milestone payments received from PerkinElmer as a reduction in research and development costs as the services are performed. Amounts received in advance of services performed are recorded as accrued liabilities until the services for which the payment has been received have been performed. The Company has received milestone payments related to this agreement of approximately $90,000 and incurred approximately $57,000 of research and development of costs during the nine months ended September 30, 2013.

	In June 2013, the Company entered into a Research Agreement with Illumina, Inc. (“Illumina”) pursuant to which the parties will work together to evaluate the potential for integrating the Company’s transrenal technology for isolating, extracting and genetic analysis of nucleic acids from urine with Illumina’s genetic analysis sequencing technology (the “Research Plan”). The parties have agreed that all results and reagents from the Research Plan will be shared between the parties. The Agreement will terminate upon the earlier of 30 days after completion of the Research Plan or the one year anniversary of the Agreement unless extended by mutual written agreement.

	In August 2013, the Company entered into a Clinical Trial Agreement with the University of Southern California (“USC”), pursuant to which USC will provide the principal investigator and conduct the clinical trial related to the genetic characterization of metastatic colorectal cancers. Under the agreement, the Company is committed to pay USC approximately $232,000 for services provided. As of September 30, 2013, the Company has not incurred any expense related to this agreement.

	Employment Agreements

	In January 2013, the Company entered into an employment agreement with Mark Erlander, Ph.D. in which he agreed to serve as Chief Scientific Officer. Dr. Erlander’s salary is $200,000 per year. Dr. Erlander is eligible to receive a cash bonus of up to 50% of his base salary per year at the discretion of the Compensation Committee based on goals mutually agreed upon by Dr. Erlander, the CEO and the Board of Directors. In connection with his employment, Dr. Erlander was granted a stock option to purchase 200,000 shares of common stock at an exercise price of $7.04. The option vests ratably over a four year period. If the Company terminates Dr. Erlander without cause, he is entitled to severance benefits equal to six months of his base salary.

	In June 2013, the Compensation Committee approved an increase to the salaries of the CEO and CFO to $350,000 and $220,000, respectively. In addition, the CEO and CFO were granted options to purchase 200,000 and 60,000 shares of common stock, respectively. The options have an exercise price of $6.00 and vest ratably over a four year period.

	Public Offering and Controlled Equity Offering

	On January 25, 2013 the Company filed a Form S-3 Registration Statement to offer and sell in one or more offerings, any combination of common stock, preferred stock, warrants, or units having an aggregate initial offering price not exceeding $150,000,000. The preferred stock, warrants, and units may be convertible or exercisable or exchangeable for common stock or preferred stock or other Trovagene securities. This form was declared effective on February 4, 2013. In addition, in connection with the Form S-3, the Company entered into an agreement with Cantor Fitzgerald & Co. (“Agent”) on January 25, 2013 to issue and sell up to $30,000,000 of shares of common stock through them. As payment for its services, the Agent is entitled to a 3% commission on gross proceeds. The Company has received gross proceeds of approximately $4.2 million from the sale of 488,476 shares of its common stock through September 30, 2013 under the agreement with the Agent. In addition, the Company has received gross proceeds of approximately $15.0 million from the sale of 2,142,857 shares of its common stock through a registered direct offering. in July 2013.

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	9 Months Ended
Net Loss Per Share (Tables)	Sep. 30, 2013
Net Loss Per Share	'
Schedule of antidilutive securities excluded from the calculation of diluted loss per share	'


		September 30,
		2013	2012
	Options to purchase Common Stock	3,894,044	3,295,066
	Warrants to purchase Common Stock	6,306,582	5,729,754
	Series A Convertible Preferred Stock	63,125	99,583
		10,263,751	9,124,403

Accounting_for_ShareBased_Paym1

Accounting for Share-Based Payments (Tables)	9 Months Ended
Accounting for Share-Based Payments (Tables)	Sep. 30, 2013
Accounting for Share-Based Payments	'
Schedule of stock-based compensation expense	'


		Three Months						Nine Months
		Ended September 30,						Ended September 30,
		2013			2012			2013		2012
	Included in research and development expense	$	124,447		$	37,399		$	426,656	$	68,879
	Included in general and administrative expense	844,629			92,960			1,231,237		280,131
	Total stock-based compensation expense	$	969,076		$	130,359		$	1,657,893	$	349,010
Schedule of assumptions to estimate fair value of stock option awards	'


		Nine Months		Nine Months
		Ended		Ended
		September		September
		30, 2013		30, 2012
	Risk-free interest rate	0.74-1.48	%	0.62-1.04	%
	Dividend yield	0	%	0	%
	Expected volatility	95-100	%	90	%
	Expected term (in years)	5 yrs		5 yrs
Summary of stock option activity and of changes in stock options outstanding under the Plan	'


		Number of		Weighted Average			Intrinsic
		Options		Exercise Price			Value
				Per Share
	Balance outstanding, December 31, 2012	3,711,303		$	4.69
	Granted	710,427		$	6.69
	Exercised	(41,667	)	$	4.5
	Forfeited	(486,019	)	$	4.32
	Balance outstanding, September 30, 2013	3,894,044		$	5.11		$	9,645,929
	Exercisable at September 30, 2013	2,084,383		$	5.6		$	4,770,228
Summary of warrant activity	'


		Number		Weighted			Remaining
		of		Average			Contractual Term
		Warrants		Exercise			Years
				Price
	Balance outstanding, December 31, 2012	6,985,070		$	3.96		5.41
	Granted	50,000		$	8		2.38
	Exercised	(728,488	)	$	4.99		4.34
	Balance outstanding, September 30, 2013	6,306,582		$	3.88		4.68

Derivative_Financial_Instrumen1

Derivative Financial Instruments - Warrants (Tables)	9 Months Ended
	Sep. 30, 2013
Black-Scholes option pricing method	'
Derivative financial instruments	'
Schedule of assumptions used to determine the fair value of the warrants	'


		Nine Months Ended			Nine Months Ended
		September 30, 2013			September 30, 2012
	Estimated fair value of Trovagene common stock	$	6.26-7.18		$	1.20-3.07
	Expected warrant term	1 months — 5.8 years			1 month - 6 years
	Risk-free interest rate	0.03-1.41%			0.09-0.92%
	Expected volatility	95 -100%			90%
	Dividend yield	0%			0%

Schedule of components of changes in the Company's derivative financial instruments liability balance	'


	Date	Description		Warrants		Derivative
						Instrument
						Liability

	December 31, 2012	Balance of derivative financial instruments liability		1,087,060		$	6,252,760

		Change in fair value of warrants during the nine months ended September 30, 2013 recognized as a loss in the statement of operations		—		28,524

	September 30, 2013	Balance of derivative financial instruments liability		1,087,060		$	6,281,284
Binomial option pricing method	'
Derivative financial instruments	'
Schedule of components of changes in the Company's derivative financial instruments liability balance	'


	Date	Number of		Derivative			Change In			Ending
		Price Protected		Liability For			Fair			Balance
		Units		Issued Units			value of			Derivative
							Derivative			Liability
							Liability For
							Previously
							Outstanding
							Price
							Protected
							Units
	December 31, 2012	1,288,650		$	1,171,463		$	1,341,405		$	2,512,868
	Reclassification of derivative liability to equity	(1,288,650	)				(5,417,871		)	(5,417,871		)
	Change in fair value of warrants during the nine months ended September 30, 2013 recognized as a loss in the statement of operations	—		—			2,905,003			2,905,003
	September 30, 2013	—		$	1,171,463		$	(1,171,463	)	$	—

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2013

Fair Value Measurements

Schedule of the Company's liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy

Liabilities:

Quoted Prices

Significant

Balance as of

Other

Unobservable

December 31, 2012

Active

Observable

Inputs

Markets

Inputs

(Level 3)

for Identical

(Level 2)

Assets and

Liabilities

(Level 1)

Derivative liabilities related to warrants

—

8,765,628

Quoted Prices

Significant

Balance as of

Other

Unobservable

September 30,

Active

Observable

Inputs

2013

Markets

Inputs

(Level 3)

for Identical

(Level 2)

Assets and

Liabilities

(Level 1)

Assets:

Money market fund (1)

27,000,044

—

27,000,044

Liabilities:

Derivative liabilities related to warrants

—

6,281,284

(1)Included as a component of cash and cash equivalents on the accompanying consolidated condensed balance sheet.

Schedule of changes in the fair value of the Company's Level 3 liabilities

Description

Balance at

Fair Value of

Fair value of

Unrealized

Balance as of

December 31,

Warrants

New Warrants

(gains) or

September 30,

2012

Reclassified to

Issued During

losses

2013

Additional Paid in

the Period

Capital

Derivative liabilities related to Warrants

8,765,628

(5,417,871

)

—

2,933,527

6,281,284

Business_Overview_and_Basis_of1

Business Overview and Basis of Presentation (Details)	0 Months Ended
Business Overview and Basis of Presentation (Details)	24-May-12
Business Overview and Basis of Presentation	'
Reverse stock split	0.1667

Net_Loss_Per_Share_Details

Net Loss Per Share (Details)	9 Months Ended
Net Loss Per Share (Details)	Sep. 30, 2013	Sep. 30, 2012
Net Loss Per Share	'	'
Antidilutive securities excluded from the calculation of diluted loss per share (in shares)	10,263,751	9,124,403
Options to purchase Common Stock	'	'
Net Loss Per Share	'	'
Antidilutive securities excluded from the calculation of diluted loss per share (in shares)	3,894,044	3,295,066
Warrants to purchase Common Stock	'	'
Net Loss Per Share	'	'
Antidilutive securities excluded from the calculation of diluted loss per share (in shares)	6,306,582	5,729,754
Series A Convertible Preferred Stock	'	'
Net Loss Per Share	'	'
Antidilutive securities excluded from the calculation of diluted loss per share (in shares)	63,125	99,583

Accounting_for_ShareBased_Paym2

Accounting for Share-Based Payments (Details) (USD $)	3 Months Ended		9 Months Ended
Accounting for Share-Based Payments (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Stock-based compensation expense	'	'	'	'
Total stock-based compensation expense	$969,076	$130,359	$1,657,893	$349,010
Included in research and development expense	'	'	'	'
Stock-based compensation expense	'	'	'	'
Total stock-based compensation expense	124,447	37,399	426,656	68,879
Included in general and administrative expense	'	'	'	'
Stock-based compensation expense	'	'	'	'
Total stock-based compensation expense	$844,629	$92,960	$1,231,237	$280,131

Accounting_for_ShareBased_Paym3

Accounting for Share-Based Payments (Details 2) (USD $)

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2013

Jun. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Jul. 18, 2013

Jul. 17, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Service Agreement

Stock options

Director [Member]

Minimum

Maximum

Unrecognized compensation cost

$3,170,227

$1,457,061

Weighted-average remaining vesting period for recognition

'3 years

'4 years

Weighted-average assumptions

Risk-free interest rate (as a percent)

0.74%

0.62%

1.48%

1.04%

Risk-free interest rate (as a percent)

0.42%

Dividend yield (as a percent)

0.00%

Dividend yield (as a percent)

0.00%

Expected volatility (as a percent)

90.00%

95.00%

100.00%

Expected volatility (as a percent)

97.00%

Expected term

'5 years

Expected term

'3 years

Number of Options

Balance outstanding at the beginning of the period (in shares)

3,711,303

Granted (in shares)

710,427

90,000

Exercised (in shares)

-41,667

Forfeited (in shares)

-486,019

Balance outstanding at the end of the period (in shares)

3,894,044

Exercisable at the end of the period (in shares)

2,084,383

Weighted Average Exercise Price Per Share

Balance outstanding at the beginning of the period (in dollars per share)

$4.69

Granted (in dollars per share)

$6.69

Exercised (in dollars per share)

$4.50

Forfeited (in dollars per share)

$4.32

Balance outstanding at the end of the period (in dollars per share)

$5.11

Exercisable at the end of the period (in dollars per share)

$5.60

Intrinsic Value

Fair value of option granted

500,000

Outstanding

9,645,929

Exercisable at the end of the period

4,770,228

Number of options issued over the authorized number of options in the Plan

260,000

Number of authorized shares

6,000,000

3,666,667

Option overage liability

23,024

Number of Warrants

Balance of warrants outstanding at the beginning of the period (in shares)

6,985,070

Granted (in shares)

50,000

Exercised (in shares)

-728,488

Balance of warrants outstanding at the end of the period (in shares)

6,306,582

Weighted Average Exercise Price

Warrants outstanding at the beginning of the period (in dollars per share)

$3.96

Granted (in dollars per share)

Exercised (in dollars per share)

$4.99

Warrants outstanding at the end of the period (in dollars per share)

$3.88

Warrants

Warrants issued

50,000

Exercise price of warrants (in dollars per share)

Fair value of award recorded as stock based compensation expense

$198,791

Remaining Contractual Term

Balance of warrants outstanding at the begining of the period

'5 years 4 months 28 days

Granted

'2 years 4 months 17 days

Exercised

'4 years 4 months 2 days

Balance of warrants outstanding at the end of the period

'4 years 8 months 5 days

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	9 Months Ended	11 Months Ended	12 Months Ended
Stockholders' Equity (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2007	Dec. 31, 2012	Jan. 31, 2007
Net proceeds from shares of common stock sold	$18,897,388	'	'	'
Number of shares outstanding	60,600	'	95,600	'
Number of stock options exercised (in shares)	41,667	'	'	'
Exercise price of stock options exercised (in dollars per share)	$4.50	'	'	'
Common Stock	'	'	'	'
Total shares of Common Stock issued	3,413,772	'	'	'
Net proceeds from shares of common stock sold	$263	'	'	'
Shares of common stock sold	2,631,332	'	'	'
Issuance of common stock upon net exercise of warrant (in shares)	7,284	'	8,602	'
Issuance of common stock upon exercise of warrant (in shares)	715,743	'	'	'
Number of common shares issued upon conversion	36,458	7,813	'	137,739
Number of common stock issued for exercise of stock options	22,955	'	'	'
Number of stock options exercised (in shares)	22,955	'	200	'
Common Stock \| Warrant exercise price, weighted average of $5.02	'	'	'	'
Issuance of common stock upon exercise of warrant (in shares)	715,743	'	'	'
Exercise price (in dollars per share)	$5.02	'	'	'
Common Stock \| Warrant exercise price of $3.00	'	'	'	'
Issuance of common stock upon net exercise of warrant (in shares)	7,284	'	'	'
Number of warrants exercised	12,745	'	'	'
Exercise price (in dollars per share)	$3	'	'	'
Series A Convertible Preferred Stock	'	'	'	'
Number of shares converted	35,000	'	'	'
Number of shares outstanding	60,600	'	'	'

Asset_Purchase_Agreement_Detai

Asset Purchase Agreement (Details) (MultiGen Diagnostics, Inc., USD $)	1 Months Ended	9 Months Ended		170 Months Ended
	Feb. 29, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Feb. 01, 2012
	item	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Feb. 01, 2012
Merger and asset purchase activities	'	'	'	'	'
Common stock issued in connection with an asset purchase agreement (in shares)	'	125,000	125,000	125,000	'
Issuance of common stock pursuant to acquisitions	$187,500	'	$187,500	$187,500	'
Number of intangible assets to which purchase price would be allocated	1	'	'	'	'
Fair value of the contingent consideration	'	'	'	'	0
Maximum	'	'	'	'	'
Merger and asset purchase activities	'	'	'	'	'
Consideration to be paid in common stock and cash upon the achievement of specific sales and earnings targets	'	'	'	'	$3,700,000
Restricted common stock	'	'	'	'	'
Merger and asset purchase activities	'	'	'	'	'
Common stock issued in connection with an asset purchase agreement (in shares)	125,000	'	'	'	'

Derivative_Financial_Instrumen2

Derivative Financial Instruments - Warrants (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended	170 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Sep. 30, 2013
Changes in the Company's derivative financial instruments liability balance	'	'	'	'	'	'
Balance of warrants outstanding at the beginning of the period (in shares)	'	'	6,985,070	'	'	'
Balance of warrants outstanding at the end of the period (in shares)	6,306,582	'	6,306,582	'	6,985,070	6,306,582
Balance of derivative financial instruments liability at the beginning of the period	'	'	$8,765,628	'	'	'
Reclassification of derivative liability to equity	'	'	-5,417,871	-3,317,463	-3,317,463	-8,735,334
Change in fair value of warrants recognized as a loss in the statement of operations	1,317,360	-388,750	2,933,527	1,824,565	'	8,428,326
Balance of derivative financial instruments liability at the end of the period	6,281,284	'	6,281,284	'	8,765,628	6,281,284
Binomial option pricing method \| Change in Fair value of Derivative Liability For Previously Outstanding Price Protected Units	'	'	'	'	'	'
Changes in the Company's derivative financial instruments liability balance	'	'	'	'	'	'
Balance of derivative financial instruments liability at the beginning of the period	'	'	1,341,405	'	'	'
Reclassification of derivative liability to equity	'	'	-5,417,871	'	'	'
Change in fair value of warrants recognized as a loss in the statement of operations	'	'	2,905,003	'	'	'
Balance of derivative financial instruments liability at the end of the period	-1,171,463	'	-1,171,463	'	'	-1,171,463
Binomial option pricing method \| Derivative Liability For Issued Units	'	'	'	'	'	'
Changes in the Company's derivative financial instruments liability balance	'	'	'	'	'	'
Balance of derivative financial instruments liability at the end of the period	1,171,463	'	1,171,463	'	1,171,463	1,171,463
Warrants \| Black-Scholes option pricing method	'	'	'	'	'	'
Range of assumptions used to determine the fair value of warrants	'	'	'	'	'	'
Expected volatility (as a percent)	'	'	'	90.00%	'	'
Dividend yield (as a percent)	'	'	0.00%	0.00%	'	'
Changes in the Company's derivative financial instruments liability balance	'	'	'	'	'	'
Balance of warrants outstanding at the beginning of the period (in shares)	'	'	1,087,060	'	'	'
Balance of warrants outstanding at the end of the period (in shares)	1,087,060	'	1,087,060	'	'	1,087,060
Balance of derivative financial instruments liability at the beginning of the period	'	'	6,252,760	'	'	'
Change in fair value of warrants recognized as a loss in the statement of operations	'	'	28,524	'	'	'
Balance of derivative financial instruments liability at the end of the period	6,281,284	'	6,281,284	'	'	6,281,284
Warrants \| Black-Scholes option pricing method \| Minimum	'	'	'	'	'	'
Range of assumptions used to determine the fair value of warrants	'	'	'	'	'	'
Estimated fair value of the entity's common stock (in dollars per share)	'	'	$6.26	$1.20	'	'
Expected warrant term	'	'	'1 month	'1 month	'	'
Risk-free interest rate (as a percent)	'	'	0.03%	0.09%	'	'
Expected volatility (as a percent)	'	'	95.00%	'	'	'
Warrants \| Black-Scholes option pricing method \| Maximum	'	'	'	'	'	'
Range of assumptions used to determine the fair value of warrants	'	'	'	'	'	'
Estimated fair value of the entity's common stock (in dollars per share)	'	'	$7.18	$3.07	'	'
Expected warrant term	'	'	'5 years 9 months 18 days	'6 years	'	'
Risk-free interest rate (as a percent)	'	'	1.41%	0.92%	'	'
Expected volatility (as a percent)	'	'	100.00%	'	'	'
Warrants \| Binomial option pricing method	'	'	'	'	'	'
Changes in the Company's derivative financial instruments liability balance	'	'	'	'	'	'
Balance of derivative financial instruments liability at the beginning of the period	'	'	2,512,868	'	'	'
Reclassification of derivative liability to equity	'	'	-5,417,871	'	'	'
Change in fair value of warrants recognized as a loss in the statement of operations	'	'	$2,905,003	'	'	'
Number of Price Protected Units at the beginning of the period (in shares)	'	'	1,288,650	'	'	'
Reclassification of derivative liability to equity	'	'	-1,288,650	'	'	'

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Liabilities:	'	'
Derivative liabilities related to warrants	$6,281,284	$8,765,628
Recurring basis \| Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)	'	'
Assets:	'	'
Money market fund	27,000,044	'
Recurring basis \| Significant Unobservable Inputs (Level 3)	'	'
Liabilities:	'	'
Derivative liabilities related to warrants	6,281,284	8,765,628
Recurring basis \| Balance at the end of the period	'	'
Liabilities:	'	'
Derivative liabilities related to warrants	6,281,284	8,765,628
Assets:	'	'
Money market fund	$27,000,044	'

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 2) (Warrants, USD $)	9 Months Ended
Fair Value Measurements (Details 2) (Warrants, USD $)	Sep. 30, 2013
Warrants	'
Reconciliation of the beginning and ending balances	'
Balance at the beginning of the period	$8,765,628
Fair Value of Warrants Reclassified to Additional Paid in Capital	-5,417,871
Fair value of New Warrants Issued During the Period	0
Unrealized (gains) or losses	2,933,527
Balance at the end of the period	$6,281,284

Debt_Details

Debt (Details) (USD $)	9 Months Ended
Debt (Details) (USD $)	Sep. 30, 2013	Jun. 30, 2013
Equipment Line of Credit	'	'
Amount borrowed included in current liabilities	$147,618	'
Amount borrowed, long-term liabilities	370,431	'
Loan and Security Agreement	'	'
Equipment Line of Credit	'	'
Maximum borrowing capacity of credit facility	'	1,000,000
Amount borrowed	515,964	'
Amount borrowed included in current liabilities	147,618	'
Amount borrowed, long-term liabilities	370,431	'
Accrued interest	2,085	'
Fixed interest rate to determine variable interest (as a percent)	5.00%	'
Variable spread over U.S. Treasury Note rate of interest (as a percent)	4.60%	'
Period for payment of principal and interest after date of advances	'30 months	'
Final payment as a percentage of total amounts borrowed	7.00%	'
Interest expenses recorded	$6,931	'

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)

3 Months Ended

9 Months Ended

170 Months Ended

9 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

8 Months Ended

1 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Apr. 25, 2013

Jun. 30, 2013

Aug. 31, 2013

Jan. 31, 2013

Jul. 31, 2013

Jan. 25, 2013

Sep. 30, 2013

Jan. 25, 2013

Jun. 30, 2013

Stock options

Research and Development Agreements

Employment agreement with Mark Erlander, Ph.D.

Public Offering and Controlled Equity Offering

CFO

CEO

MDACC

PerkinElmer Health Sciences, Inc.

Illumina

USC

Maximum

Stock options

Maximum

Agent

Stock options

HCC Field

Other fields

Maximum

Commitments and contingencies

Amount committed to be paid

$152,900

$232,000

Research and development expense

915,457

511,433

2,661,551

1,326,197

20,111,002

107,740

57,000

Period from the end of proof of principle work on certain fields within which the exclusive option is exercisable

'15 days

Period to negotiate a license agreement if the exclusive option is exercised

'60 days

Period during which the license agreement must first be offered to PerkinElmer

'1 year

Compensation per year

200,000

220,000

350,000

Receipt of milestone payments

90,000

Period of termination of agreement, after completion of the Research Plan

'30 days

Period of termination of agreement, on its anniversary unless extended by mutual written agreement

'1 year

Bonus as percentage of base salary

50.00%

Award granted (in shares)

710,427

200,000

60,000

200,000

Exercise price of award granted (in dollars per share)

$6.69

$7.04

Vesting period of options

'4 years

Period of base compensation which would be received as severance payment

'6 months

Aggregate initial offering price

150,000,000

30,000,000

Commission as percentage of gross proceeds

3.00%

Gross proceeds from sale of shares

$15,000,000

$4,200,000

Number of shares sold

18,891,949

15,478,177

2,142,857

488,476